Skip to main content

Advertisement

ADVERTISEMENT

Commentary

Commentary
12/20/2023
Clinicians should consider both the physical and psychological aspects of living with vitiligo and implement measures to identify and efficaciously address them, which can improve patient adherence, clinical outcomes, patient well-being, and...
Clinicians should consider both the physical and psychological aspects of living with vitiligo and implement measures to identify and efficaciously address them, which can improve patient adherence, clinical outcomes, patient well-being, and...
Clinicians should consider both...
12/20/2023
First Report Managed Care
Commentary
12/20/2023
In July 2023, GoodRx announced the launch of a new app known as Medicine Cabinet. In the press release, the company described the novel app as “a comprehensive solution designed to help consumers seamlessly manage their medications. Medicine...
In July 2023, GoodRx announced the launch of a new app known as Medicine Cabinet. In the press release, the company described the novel app as “a comprehensive solution designed to help consumers seamlessly manage their medications. Medicine...
In July 2023, GoodRx announced...
12/20/2023
First Report Managed Care
David Zawrotny Headshot
Commentary
12/19/2023
David Zawrotny, Chief Service Officer at RetireeFirst, the premier Retiree Benefits Management provider, offers insights into enhancing the experience and outcomes for group plan sponsors and their retirees via industry-leading strategy,...
David Zawrotny, Chief Service Officer at RetireeFirst, the premier Retiree Benefits Management provider, offers insights into enhancing the experience and outcomes for group plan sponsors and their retirees via industry-leading strategy,...
David Zawrotny, Chief Service...
12/19/2023
First Report Managed Care

Advertisement

Commentary
12/14/2023
While the majority of Janus kinase inhibitors (JAKs) are available in oral formulations, in July 2022, the FDA approved ruxolitinib cream 1.5% as the only topical formulation of a selective JAK (JAK1/JAK2) inhibitor approved in the US,...
While the majority of Janus kinase inhibitors (JAKs) are available in oral formulations, in July 2022, the FDA approved ruxolitinib cream 1.5% as the only topical formulation of a selective JAK (JAK1/JAK2) inhibitor approved in the US,...
While the majority of Janus...
12/14/2023
First Report Managed Care
Commentary
12/14/2023
Prescription digital therapeutics (PDTs) allow patients and prescribers to work collaboratively and to use ongoing technological advances to diagnose, treat, and manage various conditions effectively. Unfortunately, it appears that a lack of...
Prescription digital therapeutics (PDTs) allow patients and prescribers to work collaboratively and to use ongoing technological advances to diagnose, treat, and manage various conditions effectively. Unfortunately, it appears that a lack of...
Prescription digital...
12/14/2023
First Report Managed Care
Commentary
11/28/2023
Prescription digital therapeutics offer the potential to improve adherence and clinical outcomes while decreasing direct and indirect costs, addressing gaps in care, and enabling patients to take an active role in their care.
Prescription digital therapeutics offer the potential to improve adherence and clinical outcomes while decreasing direct and indirect costs, addressing gaps in care, and enabling patients to take an active role in their care.
Prescription digital...
11/28/2023
First Report Managed Care

Advertisement

Commentary
11/20/2023
Since nonsegmental vitiligo is the most common type of vitiligo, the availability of the targeted therapy, Opzelura (topical ruxolitinib) cream, has the potential to help many patients living with vitiligo when appropriate. Improving access...
Since nonsegmental vitiligo is the most common type of vitiligo, the availability of the targeted therapy, Opzelura (topical ruxolitinib) cream, has the potential to help many patients living with vitiligo when appropriate. Improving access...
Since nonsegmental vitiligo is...
11/20/2023
First Report Managed Care
Commentary
11/16/2023
The health care community needs another tool to support its efforts to improve care while still managing testing use and costs. Lab benefit managers (LBMs) can provide the expertise to ensure the right tests are ordered at the right times to...
The health care community needs another tool to support its efforts to improve care while still managing testing use and costs. Lab benefit managers (LBMs) can provide the expertise to ensure the right tests are ordered at the right times to...
The health care community needs...
11/16/2023
First Report Managed Care
Commentary
11/16/2023

By Ram Krishnan, CEO of Valant

By Ram Krishnan, CEO of Valant ...
Clinicians use multiple modalities to address different patients’ needs, including dialectical behavior therapy (DBT), which is evidence-based and useful for managing personality disorders and interpersonal conflicts. Evidence suggests that...
Clinicians use multiple modalities to address different patients’ needs, including dialectical behavior therapy (DBT), which is evidence-based and useful for managing personality disorders and interpersonal conflicts. Evidence suggests that...
Clinicians use multiple...
11/16/2023
First Report Managed Care

Advertisement

Commentary
11/09/2023
As the number of PDTs continues to enter the market, it is important that clinicians and patients are aware of the regulatory processes instituted by the FDA to ensure the efficacy and safety of PDTs, and knowledge about the meticulous and...
As the number of PDTs continues to enter the market, it is important that clinicians and patients are aware of the regulatory processes instituted by the FDA to ensure the efficacy and safety of PDTs, and knowledge about the meticulous and...
As the number of PDTs continues...
11/09/2023
First Report Managed Care

Advertisement